欢迎访问ProbeChem中文网站，英文网站请访问www.probechem.com
    英文 |     中文

产品咨询: sales@probechem.com
订购: order@probechem.com

首页-抗体和重组蛋白-Biosimilar Antibody-Monalizumab
Monalizumab

Chemical Structure : Monalizumab

CAS No.: 1228763-95-8

加入收藏

Monalizumab (Anti-human CD159a mAb, human IgG4-Kappa; IPH2201)

货号: PC-Ab1087Not For Human Use, Lab Use Only.

Monalizumab (IPH2201) is a blocking antibody that prevents the inhibition of CD8+ T cells and NK cell by tumor cells expressing HLA-E. The first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E. Monalizumab targets NKG2A receptors expressed on tumor infiltrating cytotoxic CD8 T lymphocytes and NK cells. NKG2A is an inhibitory receptor binding HLA-E. By expressin

规格 价格 库存 数量
1 mg ￥3580 In stock
5 mg ￥7580 In stock
10 mg ￥12800 In stock
100 mg Get quote
获取报价单
* 请选择数量再加入购物车
 or Bulk Inquiry

大包装，大折扣！

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

纯度 & COA & 质检文件 纯度: >98% (HPLC) Select Batch:

生物&药学活性

Monalizumab (IPH2201) is a blocking antibody that prevents the inhibition of CD8+ T cells and NK cell by tumor cells expressing HLA-E. The first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E. Monalizumab targets NKG2A receptors expressed on tumor infiltrating cytotoxic CD8 T lymphocytes and NK cells. NKG2A is an inhibitory receptor binding HLA-E. By expressing HLA-E, cancer cells can protect themselves from killing by NKG2A+ immune cells.

物理化学性质&存储条件

分子量
分子式 Human IgG4-Kappa
外观性状 Solid
CAS No.
储存条件
固体粉末
-20 °C 12 个月; 4°C 6 个月
配置液
-80 °C 6 个月; -20°C 6 个月
Shipping
Solubility

PBS, pH 7.0 Contains no stabilizers or preservatives
Chemical Name/SMILES

Monalizumab; IPH2201; IPH 2201; anti human NKG2A; anti human CD159Aa; anti human KLRC1; 1228763-95-8

参考文献

1. 1, van Hall T, et al. J Immunother Cancer. 2019 Oct 17;7(1):263. 2, André P, et al. Cell. 2018 Dec 13;175(7):1731-1743.e13. 3, Borst L, et al. Clin Cancer Res. 2020 Nov 1;26(21):5549-5556. 4, Tinker AV, et al. Clin Cancer Res. 2019 Oct 15;25(20):6052-6060. 5, Yaqinuddin A, et al. Med Hypotheses. 2020 Apr 22;140:109777.

备案号：沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

联系我们 sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

询单

  • *产品名称:
  • *姓名:
  • *邮箱:
  • *公司名称:
  • *询单数量:
  • *国籍:
  • 询单信息: